The India minimally invasive biopsy techniques market size reached USD 93.78 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 271.56 Million by 2033, exhibiting a growth rate (CAGR) of 11.60% during 2025-2033. The India minimally invasive biopsy techniques market is driven by advancements in liquid biopsy technology, increasing cancer cases, government healthcare initiatives, expanding diagnostic infrastructure, rising preference for less invasive procedures, improved imaging modalities, private sector investments, and enhanced accessibility to precision diagnostics across urban and rural regions.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024 |
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 93.78 Million |
Market Forecast in 2033 | USD 271.56 Million |
Market Growth Rate (2025-2033) | 11.60% |
Rising Incidence of Cancer
The rise in cancer prevalence in India has been a strong contributor to the need for enhanced diagnostic procedures, such as minimally invasive biopsies. The Indian Council of Medical Research (ICMR) estimated over 1.4 million cancer cases in 2023 in India. This prevalence of cancer cases requires effective and precise diagnostic tests. Minimally invasive biopsies are beneficial in numerous ways compared to conventional methods, including less pain for the patient, quicker recovery periods, and fewer complications. These factors render them especially apt for the detection and treatment of cancer at the initial stages, in line with the healthcare system's focus on enhanced patient outcomes. The National Cancer Registry Programme (NCRP) instituted by the ICMR in 1982 has played an important role in monitoring cancer incidence and trends throughout the country. NCRP's collected data point toward influence burden of cancer, reinforcing the necessity for effective methods of diagnosis. The introduction of minimally invasive biopsy procedures is a reactive measure to this necessity, enabling timely and accurate diagnosis, which is essential for proper treatment planning. In addition, public health programs for cancer awareness and early detection have led to more people presenting themselves for diagnostic testing. With higher awareness, more patients are choosing minimally invasive procedures because they are less invasive and have shorter recovery times. This patient preference also propels the market for these advanced diagnostic methods.
Government Initiatives and Increased Healthcare Funding
Indian government's efforts to enhance healthcare infrastructure and services have been instrumental in encouraging the use of cutting-edge medical technologies, such as minimally invasive biopsy methods. In the Union Budget 2021-22, the government provided INR 2,23,846 crore for healthcare, a significant upsurge compared to earlier years. The emphasis on the development of healthcare services has seen the creation of health and wellness centers in rural and urban regions, improving diagnostic service accessibility. The construction of public health laboratory integration and critical care blocks in hospitals has enhanced the infrastructure in place for the enactment of advanced diagnostic methods, such as minimally invasive biopsies. These programs ensure that patients from all regions gain access to timely and reliable diagnostic services, hence promoting the widespread use of these methods. Additionally, the government's focus on universal health coverage and decreasing out-of-pocket spending has brought expensive diagnostic procedures within reach. The Economic Survey 2022-23 pointed out that the budgeted spending of the Central and State Governments on the health sector surged to 2.1% of GDP in FY23 from 1.6% in FY21. This substantial funding has made it possible to make investments in sophisticated medical equipment and provide training for health practitioners to enable the efficient deployment of minimally invasive biopsy procedures nationwide.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the region/country level for 2025-2033. Our report has categorized the market based on product offered, technique, circulating biomarker, application, and end user.
Product Offered Insights:
The report has provided a detailed breakup and analysis of the market based on the product offered. This includes tests, kits consumables, and instruments.
Technique Insights:
A detailed breakup and analysis of the market based on technique have also been provided in the report. This includes liquid biopsy, optical biopsy, brush biopsy, pigmented lesion assays, and others.
Circulating Biomarker Insights:
A detailed breakup and analysis of the market based on the circulating biomarker have also been provided in the report. This includes circulating tumor cells (CTCs), cell free DNA (cfDNA), circulating tumor DNA (ctDNA), extracellular vesicles, and others.
Application Insights:
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes clinical (treatment monitoring, prognosis recurrence monitoring, treatment selection, and others) and therapeutic (breast cancer, lung cancer, prostate cancer, colorectal cancer, and others).
End User Insights:
A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals clinics, ambulatory care centers, and academic research institutions.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include North India, South India, East India, and West India.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Products Offered Covered | Tests, Kits Consumables, Instruments |
Techniques Covered | Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others |
Circulating Biomarkers Covered | Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Others |
Applications Covered |
|
End Users Covered | Hospitals Clinics, Ambulatory Care Centers, Academic Research Institutions |
Regions Covered | North India, South India, East India, West India |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
Key Benefits for Stakeholders: